Top

Journal of General Internal Medicine

Published in:

Open Access 01-07-2007 | Perspectives

Bioidentical Hormones for Menopausal Hormone Therapy: Variation on a Theme

Authors: Adriane Fugh-Berman, MD, Jenna Bythrow, MS candidate

Published in: Journal of General Internal Medicine | Issue 7/2007

Abstract

BACKGROUND

Progesterone creams and natural or bioidentical compounded estrogen preparations are being promoted to consumers as safe alternatives to conventional menopausal hormone therapy and as health-promoting tonics. No reliable data support these claims.

SAFETY

Natural hormones, including estradiol, estriol, estrone, and progesterone, can be expected to have the same adverse event profile as conventional menopausal hormone regimens.

SALIVARY HORMONE TESTS

Salivary tests may be used to persuade asymptomatic consumers to use hormones (or symptomatic patients to use higher doses than those needed to mitigate symptoms), a practice that can be expected to result in adverse events.

Hogg JA. Steroids, the steroid community, and Upjohn in perspective: a profile of innovation. Steroids. 1002;57:593–616.

Mahaguna V, McDermott JM, Zhang F, Ochoa F. Investigation of product quality between extemporaneously compounded progesterone vaginal suppositories and an approved progesterone vaginal gel. Drug Dev Ind Pharm. 2004;30(10):1069–78.PubMed

Food and Drug Administration. Available via the internet at http://www.cfsan.fda.gov/~dms/cfsand04.html. Accessed 19 Sep 2006.

Women’s International Pharmacy. Especially Designed for Women. Youngtown, Ariz, and Madison, Wisc., USA: Women’s International Pharmacy; 8–9 April 2002.

Premier Pharmacy. Available at http://premier-pharmacy.com/abouthrt3.html. Accessed Jul 2005. (PDF no longer available)

MedXLife. Available at http://medxlife.com/getArticles.asp?aId=54&categoryId=10. Accessed 5 Nov 2004.

College Pharmacy. Available at http://www.collegepharmacy.com/specializations/biest.asp. Accessed Jul 2005.

Wren BG, Champion SM, Willetts K, Manga RZ, Eden JA. Transdermal progesterone and its effect on vasomotor symptoms, blood lipid levels, bone metabolic markers, moods, and quality of life for postmenopausal women. Menopause. 2003;10(1):13–8.PubMed

Leonetti HB, Longo S, Anasti JN. Transdermal progesterone cream for vasomotor symptoms and postmenopausal bone loss. Obstet Gynecol. 1999;94:225–8.PubMed

10.

Lee J. Natural Progesterone: The Multiple Roles of a Remarkable Hormone. Sebastopol, Calif: BLL Publishing; 1993.

11.

Lee JR, Zava D, Hopkins V. What Your Doctor May Not Tell You About Breast Cancer! How Hormone Balance Can Help Save Your Life. New York, NY: Warner Books; 2002.

12.

Lee JR, Hanley J, Hopkins V. What Your Doctor May Not Tell You About Premenopause: Balance Your Hormones and Your Life from Thirty to Fifty. New York, NY: Warner Books; 1999.

13.

Lee JR, Hopkins V. What Your Doctor May Not Tell You About Menopause: The Breakthrough Book on Natural Progesterone. New York, NY: Warner Books; 2004.

14.

AltMedNetwork. Available at http://www.altmednetwork.net/whealth/progest_crm.html. Accessed Jun 2005.

15.

Pure Essence Labs. Available at http://www.pureessencelabs.com/pdf/femcreme.pdf. Accessed Jun 2005. (PDF no longer available)

16.

Sommers S. Ageless: the naked truth about bioidentical hormones. New York, NY: Crown Publishers; 2006:7, 23, 71.0.

17.

DrErika.com. Available at http://drerika.com/EN/index.html. Accessed 31 Oct 2005.

18.

Hotze S. Hormones and the woman’s life cycles. Available at http://www.drhotze.com/EN/online_articles/389.html. Accessed Feb 2007

19.

Adams C, Cannell S. Women’s beliefs about “natural” hormones and natural hormone replacement therapy. Menopause. 2001;8(6):433–40.PubMed

20.

Writing group for the Women’s Health Initiative investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–33.

21.

Anderson GL, Limacher M, Assaf AR, et al., Women’s Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA. 2004;291(14):1701–12.

22.

Cherry N, Gilmour K, Hannaford P, et al., ESPRIT team. Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial. Lancet. 2002;360(9350):2001–8.

23.

ESPRIT. Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomized placebo controlled trial. Lancet. 2002;360:2001–8.

24.

Hendrix SL, Wassertheil-Smoller S, Johnson KC, et al.,WHI Investigators. Effects of conjugated equine estrogen on stroke in the Women’s Health Initiative. Circulation. 2006;113(20):2425–34.

25.

Wassertheil-Smoller S, Hendrix SL, Limacher M, et al., WHI Investigators. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women’s Health Initiative: a randomized trial. JAMA. 2003;289(20):2673–84.

26.

Shumaker SA, Legault C, Rapp SR, et al., WHIMS Investigators. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women’s Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003;289(20):2651–62.

27.

Shumaker SA, Legault C, Kuller L, et al., Women’s Health Initiative Memory Study. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women’s Health Initiative Memory Study. JAMA. 2004;291(24):2947–58.

28.

Hendrix SL, Cochrane BB, Nygaard IE, et al. Effects of estrogen with and without progestin on urinary incontinence. JAMA. 2005;293(8):935–48.PubMed

29.

Hays J, Ockene JK, Brunner RL, et al. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med. 2003;348(19):1839–54.PubMed

30.

Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med. 2001;345(17):1243–9.PubMed

31.

Lemon HM. Pathophysiologic considerations in the treatment of menopausal patients with oestrogens; the role of oestriol in the prevention of mammary carcinoma. Acta Endocrinol Suppl (Copenh). 1980;233:17–27.

32.

Endogenous Hormones and Breast Cancer Collaborative Group. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst. 2002;94(8):606–16.

33.

Zeleniuch-Jacquotte A, Shore RE, Koenig KL, et al. Postmenopausal levels of oestrogen, androgen, and SHBG and breast cancer: long-term results of a prospective study. Br J Cancer. 2004;90(1):153–9.PubMed

34.

Manjer J, Johansson R, Berglund G, et al. Postmenopausal breast cancer risk in relation to sex steroid hormones, prolactin and SHBG (Sweden). Cancer Causes Control. 2003;14(7):599–607.PubMed

35.

Key TJ, Appleby PN, Reeves GK, et al., Endogenous Hormones Breast Cancer Collaborative Group. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst. 2003;95(16):1218–26.

36.

Onland-Moret NC, Kaaks R, van Noord PA, et al. Urinary endogenous sex hormone levels and the risk of postmenopausal breast cancer. Br J Cancer. 2003;88(9):1394–9.PubMed

37.

Yu H, Shu XO, Shi R, et al. Plasma sex steroid hormones and breast cancer risk in Chinese women. Int J Cancer. 2003;105(1):92–7.PubMed

38.

Hankinson SE, Willett WC, Manson JE, et al. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst. 1998;90:1292–1299.PubMed

39.

Lippert C, Seeger H, Mueck AO. The effect of endogenous estradiol metabolites on the proliferation of human breast cancer cells. Life Sci. 2003;72(8):877–83.PubMed

40.

Mady EA, Ramadan EE, Ossman AA. Sex steroid hormones in serum and tissue of benign and malignant breast tumor patients. Dis Markers. 2000;16(3–4):151–7.PubMed

41.

Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int J Cancer. 2005;114(3):448–54.PubMed

42.

Vashisht A, Wadsworth F, Carey A, Carey B, Studd J. A study to look at hormonal absorption of progesterone cream used in conjunction with transdermal estrogen. Gynecol Endocrinol. 2005;21(2):101–5.PubMed

43.

Wren, B. G., McFarland, K., Edwards, L. Micronised transdermal progesterone and endometrial response. Lancet 1999;354:1447–8.PubMed

44.

Leonetti HB, Wilson KJ, Anasti JN. Topical progesterone cream has an antiproliferative effect on estrogen-stimulated endometrium. Fertil Steril. 2003;79(1):221–2 (Jan).PubMed

45.

Lewis JG, McGill H, Patton VM, Elder PA. Caution on the use of saliva measurements to monitor absorption of progesterone from transdermal creams in postmenopausal women. Maturitas. 2002;41:1–6.PubMed

46.

Carey BJ, Carey AH, Patel S, Carter G, Studd JW. A study to evaluate serum and urinary hormone levels following short and long term administration of two regimens of progesterone cream in postmenopausal women. BJOG. 2000;107(6):722–6.PubMed

47.

O’Leary PO, Feddema P, Chan K, et al. Salivary, but not serum or urinary levels of progesterone are elevated after topical application of progesterone cream to pre- and postmenopausal women. Clin Endocrinol. 2000;53:615–20.

48.

Burry KA, Patton PE, Hermsmeyer K. Percutaneous absorption of progesterone in postmenopausal women treated with transdermal estrogen. Am J Obstet Gynecol. 1999;180(6 Pt 1):1504–11.PubMed

49.

Cooper A, Spencer C, Whitehead MI, Ross D, Barnard GJ, Collins WP. Systemic absorption of progesterone from Progest cream in postmenopausal women. Lancet. 1998;351(9111):1255–6.

50.

Hermann AC, Nafziger AN, Victory J, Kulaway R, Rocci ML, Bertino JS. Over-the-counter progesterone cream produces significant drug exposure compared to a Food and Drug Administration approved oral progesterone. J Clin Pharmacol. 2005;45:614–9.PubMed

51.

Boothby LA, Doering PL, Kipersztok S. Bioidentical hormone therapy: a review. Menopause. 2004;11(3):356–67.PubMed

52.

van Haaften M, Donker GH, Sie-Go DM, Haspels AA, Thijssen JH. Biochemical and histological effects of vaginal estriol and estradiol applications on the endometrium, myometrium and vagina of postmenopausal women. Gynecol Endocrinol. 1997;11(3):175–85.PubMedCrossRef

53.

Granberg S, Ylostalo P, Wikland M, Karlsson B. Endometrial sonography and histological findings in women with and without hormonal replacement therapy suffering from post menopausal bleeding. Maturitas. 1997;27:35–40.PubMed

54.

Weiderpass E, Baron JA, Adami H-O, et al. Low-potency oestrogen and risk of endometrial cancer: a case-control study. Lancet. 1999;353:1824–8.PubMed

55.

Granberg S, et al. The effects of oral estriol on the endometrium in postmenopausaul women. Maturitas. 2002;42:149–56.PubMed

56.

Scialli A, Fugh-Berman A. The effects of oral estriol on the endometrium in postmenopausal women. Maturitas. 2003;45(2):147; author reply 149.PubMed

57.

Food and Drug Administration. Food and Drug Administration Labeling Guidance for Noncontraceptive Estrogen Drug Products for the Treatment of Vasomotor Symptoms and Vulvar and Vaginal Atrophy Symptoms—Prescribing Information for Health Care Providers and Patient Labeling, revision 1. USA: Center for Drug Evaluation and Research (CDER), revision 1. Available at http://www.fda.gov/cder/guidance/index.htm; February 2004.

58.

Stanczyk FZ, Paulson RJ, Roy S. Percutaneous administration of progesterone: blood levels and endometrial protection. Menopause. 2005;12(2):232–7.PubMed

59.

Vashisht A, Wadsworth F, Carey A, Carey B, Studd J. Bleeding profiles and effects on the endometrium for women using a novel combination of transdermal oestradiol and natural progesterone cream as part of a continuous combined hormone replacement regime. BJOG. 2005;112(10):1402–6.PubMed

Title: Bioidentical Hormones for Menopausal Hormone Therapy: Variation on a Theme
Authors: Adriane Fugh-Berman, MD
Jenna Bythrow, MS candidate
Publication date: 01-07-2007
Publisher: Springer-Verlag
Published in: Journal of General Internal Medicine / Issue 7/2007
Print ISSN: 0884-8734
Electronic ISSN: 1525-1497
DOI: https://doi.org/10.1007/s11606-007-0141-4

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

BACKGROUND

SAFETY

SALIVARY HORMONE TESTS

Please log in to get access to this content

Other articles of this Issue 7/2007

The Effectiveness of β-blockers in Women With Congestive Heart Failure

Effects of Accreditation Council for Graduate Medical Education Work Hour Restrictions on Medical Student Experience

Cognitive Assessment of Older Primary Care Patients with and Without Memory Complaints

An Unusual Case of Cardiac Amyloidosis

Obese African-American Women’s Perspectives on Weight Loss and Bariatric Surgery

Weight Loss Maintenance in African–American Women: Focus Group Results and Questionnaire Development

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials